

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error or Definition	Errors
1	BRS	L1	403	TFPI	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 06:59			0
2	BRS	L2	50	TFPI-2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 06:59			0
3	BRS	L3	68	kunitz same (domain adj 1)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:00			0
4	BRS	L4	20	kunitz same (domain adj 2)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:00			0
5	BRS	L5	68	(1 or 2) same (3 or 4)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:01			0
6	BRS	L6	4	5 same (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:19			0
7	BRS	L7	4175	glycosaminoglycan	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:19			0
8	BRS	L8	314	heparin adj binding adj domain	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:20			0
9	BRS	L9	342	protease adj nexin\$1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:20			0
10	BRS	L10	0	6 same (7 or 8 or 9)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/12/0 4 07:20			0

=> d his

(FILE 'HOME' ENTERED AT 07:23:20 ON 04 DEC 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT
07:23:45 ON 04 DEC 2002

L1 3347 S TFPI
L2 221 S TFPI-2
L3 42 S KUNITZ (P) (DOMAIN 1)
L4 32 S KUNITZ (P) (DOMAIN 2)
L5 30 S (L1 OR L2) (P) (L3 OR L4)
L6 2 S L5 (P) (CHIMERIC OR FUSION)
L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)
L8 70335 S GLYCOSAMINOGLYCAN
L9 2924 S HEPARIN BINDING DOMAIN
L10 728 S PROTEASE NEXIN-1
L11 3 S L9 (P) L10
L12 1 S L7 (P) (L8 OR L11)

=> log y

FILE 'HOME' ENTERED AT 07:23:20 ON 04 DEC 2002

=> file medline caplus biosis embase scisearch agricola		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 07:23:45 ON 04 DEC 2002

FILE 'CAPLUS' ENTERED AT 07:23:45 ON 04 DEC 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 07:23:45 ON 04 DEC 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 07:23:45 ON 04 DEC 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 07:23:45 ON 04 DEC 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 07:23:45 ON 04 DEC 2002

=> s tfpi
L1 3347 TFPI

=> s tfpi-2
L2 221 TFPI-2

=> s kunitz (p) (domain 1)
L3 42 KUNITZ (P) (DOMAIN 1)

=> s kunitz (p) (domain 2)
L4 32 KUNITZ (P) (DOMAIN 2)

=> s (l1 or l2) (p) (l3 or l4)
L5 30 (L1 OR L2) (P) (L3 OR L4)

=> s l5 (p) (chimeric or fusion)
L6 2 L5 (P) (CHIMERIC OR FUSION)

=> duplicate remove l6
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L6
L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)

=> d l7 1-2 ibib abs

L7 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:340475 BIOSIS
DOCUMENT NUMBER: PREV200100340475
TITLE: Chimeric proteins.
AUTHOR(S): Innis, Michael A.; Creasey, Abba A.
ASSIGNEE: Chiron Corporation
PATENT INFORMATION: US 6174721 January 16, 2001
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Jan. 16, 2001) Vol. 1242, No. 3, pp. No
Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

AB ***Chimeric*** proteins possessing ***Kunitz*** -type
domain ***1*** of ***TFPI*** - ***2*** and
Kunitz -type ***domain*** ***2*** of ***TFPI*** are
disclosed, as are muteins of ***TFPI*** and ***TFPI*** - ***2***
. Nucleic acid sequences, expression vectors and transformed host cells
encoding and capable of producing the disclosed ***chimeric***

proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the ***chimeric*** proteins and muteins are disclosed.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:295080 CAPLUS

DOCUMENT NUMBER: 124:325361

TITLE: Chimeric proteins and muteins of tissue factor pathway inhibitors TFPI and TFPI-2

INVENTOR(S): Innis, Michael A.; Creasey, Alba A.

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604378	A2	19960215	WO 1995-US9464	19950725
WO 9604378	A3	19960314		
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5589359	A	19961231	US 1994-286521	19940805
US 5563123	A	19961008	US 1995-437841	19950509
US 5696088	A	19971209	US 1995-436175	19950509
CA 2196290	AA	19960215	CA 1995-2196290	19950725
AU 9531500	A1	19960304	AU 1995-31500	19950725
AU 710535	B2	19990923		
EP 776366	A1	19970604	EP 1995-927478	19950725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10503375	T2	19980331	JP 1995-506598	19950725
US 6174721	B1	20010116	US 1997-943682	19971014

PRIORITY APPLN. INFO.:

US 1994-286521 A 19940805
US 1995-438184 B1 19950509
WO 1995-US9464 W. 19950725

AB ***Chimeric*** proteins possessing ***Kunitz*** -type
domain ***1*** ot ***TFPI*** - ***2*** and
Kunitz -type ***domain*** ***2*** of ***TFPI*** are
provided, as are muteins of ***TFPI*** and ***TFPI*** - ***2***.
Nucleic acid sequences, expression vectors, and transformed host cells
encoding and capable of producing the disclosed ***chimeric***
proteins and muteins are also provided. ***Chimeric*** proteins were
constructed with amino acid sequences capable of binding a cell surface
component (glycosaminoglycan, heparin) such as peptide moieties from
protease nexin-1, protease nexin-2, antithrombin III, heparin cofactor II,
protein C inhibitor, platelet factor 4, bovine pancreatic trypsin
inhibitor, and ghilanten-related inhibitors. The ***chimeric***
proteins are produced as yeast .alpha.-factor ***fusion*** proteins
for secretion, or alternatively, may be expressed as a ubiquitin
fusion protein. Potential sites for N-linked glycosylation within
TFPI (Asn116.fwdarw.Gln, Asn227.fwdarw.Gln) are removed using
overlapping PCR and mutations och1, mn1, and alg3 are introduced in
transformed yeast cells to prevent the prodn. of .alpha.-1,6-polymannose
terminal carbohydrate moieties in the ***chimeric*** products.
Finally, methods for prevention and treatment of septic shock using the
chimeric proteins and muteins are described.

=> d his

(FILE 'HOME' ENTERED AT 07:23:20 ON 04 DEC 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
07:23:45 ON 04 DEC 2002

L1 3347 S TFPI
L2 221 S TFPI-2
L3 42 S KUNITZ (P) (DOMAIN 1)
L4 32 S KUNITZ (P) (DOMAIN 2)
L5 30 S (L1 OR L2) (P) (L3 OR L4)
L6 2 S L5 (P) (CHIMERIC OR FUSION)

L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)

=> s glycosaminoglycan
L8 70335 GLYCOSAMINOGLYCAN

=> s heparin binding domain
L9 2924 HEPARIN BINDING DOMAIN

=> s protease nexin-1
L10 728 PROTEASE NEXIN-1

=> s l9 (p) l10
L11 3 L9 (P) L10

=> s l7 (p) (l8 or l11)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L72 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L78 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L80 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L82 (P) '
L12 1 L7 (P) (L8 OR L11)

=> d his

(FILE 'HOME' ENTERED AT 07:23:20 ON 04 DEC 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
07:23:45 ON 04 DEC 2002

L1 3347 S TFPI
L2 221 S TFPI-2
L3 42 S KUNITZ (P) (DOMAIN 1)
L4 32 S KUNITZ (P) (DOMAIN 2)
L5 30 S (L1 OR L2) (P) (L3 OR L4)
L6 2 S L5 (P) (CHIMERIC OR FUSION)
L7 2 DUPLICATE REMOVE L6 (0 DUPLICATES REMOVED)
L8 70335 S GLYCOSAMINOGLYCAN
L9 2924 S HEPARIN BINDING DOMAIN
L10 728 S PROTEASE NEXIN-1
L11 3 S L9 (P) L10
L12 1 S L7 (P) (L8 OR L11)

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	38.25	38.46
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 07:28:12 ON 04 DEC 2002